Corporate Banner
Satellite Banner
Cell Culture
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

InSphero Announces Collaboration with NCATS

Published: Friday, March 21, 2014
Last Updated: Friday, March 21, 2014
Bookmark and Share
Study to characterize 460 NCATS anti-cancer agents in 3D tumor models generated using InSphero technology.

InSphero AG announced a collaboration with the National Institutes of Health's (NIH) National Center for Advancing Translational Sciences (NCATS) to identify anti-cancer agents with cytotoxic activity in 3D culture models. The project includes development of multi-cell type spheroids (MCTS) by InSphero in the company's 96- and 384-well GravityPLUS hanging drop plates, using tumor cell lines currently being at NCATS. InSphero will generate the 3D microtissues and provide them to NCATS to screen a collection of 460 anti-cancer agents for cytotoxic effects using assays that measure cell proliferation, tissue integrity, and tissue size. 

In the study, MCTS cultures will be explored as a model of tumors to predict the effectiveness of anti-cancer drugs. Currently, high-throughput screens to discover such agents are typically conducted in two dimensional (2D) proliferation assays using cells grown on tissue-culture treated plastic surfaces. However, it is evident that such 2D assays using cancer cell lines fail to reproduce the cellular heterogeneity of tumors, as well as the complexity of the interactions with the tumor microenvironment that are seen in viva As a consequence, compounds that appear to be cytotoxic in 2D cell proliferation assays often fail to produce an effect in vivo. 

The 3D microtissues are thought to offer a more accurate physiological representation of a tumor and its extracellular environment, including the effect of additional cell types such as endothelial and stromal cells. 3D cultures are also being used as models to investigate tumor cell sub-populations called cancer stem cells or tumor-initiating cells. These cells have self-renewal potential and are thought to drive metastasis and tumor formation. They also appear to be resistant to current chemotherapy and radiation-therapy treatments that produce cancer recurrence. 

"InSphero is excited to join forces with the expertise and resources from the NCATS team to help screen their oncology library for compounds that can kill cancer cells in the context of a more relevant tumor model system," says Jens Kelm, Ph.D., Chief Scientific Officer and co-founder of InSphero. "By co-culturing non-proliferative stromal cells in combination with tumor cell lines, the 3D spheroids more accurately reflect tumor heterogeneity and tumor microenvironments. Our system will enable direct discrimination of compounds that act specifically on the cancer cell population from those having a general cytotoxic effect." 

"Our work with InSphero is yet another example of how NCATS fosters collaborations to explore novel technologies that carry the promise to accelerate discovery of molecular therapeutic agents across multiple disease areas," said Anton Simeonov, Ph.D., acting deputy scientific director of NCATS' Division of Pre-Clinical Innovation.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 4,000+ scientific posters on ePosters
  • More than 5,300+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

InSphero Expands Global Availability of its Patented 3D Cell Culture Platforms
PerkinElmer named as exclusive distributor of InSphero 3D culture technology.
Thursday, August 06, 2015
InSphero AG Secures CHF 20 Million Series C Financing
3D cell culture company gains new long-term investor to fuel expansion of global operations and product portfolio.
Wednesday, July 15, 2015
InSphero AG Secures CHF 20 Million Series C Financing
Leading 3D cell culture company gains new long-term investor to fuel expansion of global operations and product portfolio.
Tuesday, July 14, 2015
3D Liver Spheroid Model in Use by MIP-DILI
European consortium will use 3D liver tissues to better predict drug-induced liver injury.
Friday, January 23, 2015
InSphero Wins ACES Award as Top European Academic Enterprise in Life Sciences
Second honor in three weeks continues momentum for leading supplier of 3D microtissues for in vitro toxicity and efficacy testing.
Wednesday, October 15, 2014
InSphero Named #1 Swiss Startup for 2014
Leading supplier of 3D microtissues for in vitro toxicity and efficacy testing earns top honors in annual Swiss startup competition.
Saturday, October 04, 2014
InSphero Publishes 3D Tumor-Stroma Model for Non-Small Cell Lung Cancer
PLOS One article delivers promising co-culture method to mimic tumor microenvironment, demonstrating potential for biomarker and drug discovery.
Thursday, April 24, 2014
InSphero Hires New Director of Global Marketing
Randy Strube, Ph.D. joins company to strengthen InSphero's marketing team.
Thursday, January 30, 2014
Scientific News
Stem Cells in Drug Discovery
Potential Source of Unlimited Human Test Cells, but Roadblocks Remain.
Inspiring Futuristic Innovation: Brain ‘Organoids’
Scientists create artificial brains, providing an advanced model for studying brain tumour development.
More Effective Strategy for Producing Flu Vaccines
Researchers have developed a virus backbone, allowing producers to grow vaccine viruses in mammalian cells, rather than in eggs.
Tissue Damage Is Key for Cell Reprogramming
Researchers have shown tissue damage is important for cells to return to an embryonic state for cell reprogramming.
Making Personalized Medicine a Reality
Groundbreaking technique developed at McMaster University is helping to pave the way for advances in personalized medicine.
Regenerating Diseased Hearts
Researchers from the University of Otago have probed the potential of adult stem cell types to repair diseased hearts.
Color-Coded Stem Cells
Researchers develop colour-coding tool for tracking live blood stem cells over time.
Using Cancer Cells' Mass to Predict Treatment Response
A device has been developed that can detect changes in cell mass at a minute scale.
Human Intestines and Functioning Nerves Engineered
The new technology enables the study of human health and advances the goal of regenerative medicine.
Chemical Snapshots Could Lead to Better Engineered Cartilage
Taking "chemical photographs" of the cartilage between joints and comparing it to engineered versions could lead to better implants, say researchers.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
4,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,300+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!